ZA200501418B - Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives - Google Patents
Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivativesInfo
- Publication number
- ZA200501418B ZA200501418B ZA200501418A ZA200501418A ZA200501418B ZA 200501418 B ZA200501418 B ZA 200501418B ZA 200501418 A ZA200501418 A ZA 200501418A ZA 200501418 A ZA200501418 A ZA 200501418A ZA 200501418 B ZA200501418 B ZA 200501418B
- Authority
- ZA
- South Africa
- Prior art keywords
- fluoro
- benzenesulfonate salts
- cyanopyrrolidine derivatives
- cyanopyrrolidine
- derivatives
- Prior art date
Links
- HHFUFGKACHWIAV-UHFFFAOYSA-N 4-fluoropyrrolidine-2-carbonitrile Chemical class FC1CNC(C#N)C1 HHFUFGKACHWIAV-UHFFFAOYSA-N 0.000 title 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002249821 | 2002-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200501418B true ZA200501418B (en) | 2006-10-25 |
Family
ID=31972599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200501418A ZA200501418B (en) | 2002-08-29 | 2003-08-27 | Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives |
Country Status (19)
Country | Link |
---|---|
US (1) | US7304166B2 (ja) |
EP (1) | EP1535907A4 (ja) |
JP (1) | JP3746063B2 (ja) |
KR (1) | KR100582141B1 (ja) |
CN (1) | CN1310885C (ja) |
AU (1) | AU2003261748B2 (ja) |
BR (1) | BR0313831A (ja) |
CA (1) | CA2496623C (ja) |
EA (1) | EA007613B1 (ja) |
EC (1) | ECSP055708A (ja) |
HK (1) | HK1082497A1 (ja) |
HR (1) | HRP20050205A2 (ja) |
MX (1) | MXPA05002253A (ja) |
NO (1) | NO20050867L (ja) |
NZ (1) | NZ538956A (ja) |
PL (1) | PL374664A1 (ja) |
UA (1) | UA78104C2 (ja) |
WO (1) | WO2004020407A1 (ja) |
ZA (1) | ZA200501418B (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
WO2006080401A1 (ja) | 2005-01-27 | 2006-08-03 | Mitsui Chemicals, Inc. | フッ素化プロリン誘導体の製造方法 |
JP2008024592A (ja) * | 2005-01-28 | 2008-02-07 | Taisho Pharmaceut Co Ltd | シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法 |
BRPI0609580A2 (pt) | 2005-03-22 | 2010-04-20 | Hoffmann La Roche | composto, polimorfo cristalino, processo para a sua manufatura, composições farmacêuticas que o contêm, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e utilização do composto |
CA2622472C (en) | 2005-09-14 | 2013-11-19 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
CN101360723A (zh) | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
ES2529149T3 (es) | 2007-04-03 | 2015-02-17 | Mitsubishi Tanabe Pharma Corporation | Una combinación de inhibidor de dipeptidil peptidasa IV y edulcorante para uso en el tratamiento de la obesidad |
CL2008003653A1 (es) * | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
JP2013523819A (ja) | 2010-04-06 | 2013-06-17 | アリーナ ファーマシューティカルズ, インコーポレイテッド | Gpr119レセプターのモジュレーターおよびそれに関連する障害の処置 |
KR101871011B1 (ko) | 2010-09-22 | 2018-06-25 | 아레나 파마슈티칼스, 인크. | Gpr119 수용체의 조절제 및 그와 관련된 장애의 치료 |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
CA2979033A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4432987A (en) | 1982-04-23 | 1984-02-21 | Pfizer Inc. | Crystalline benzenesulfonate salts of sultamicillin |
GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
TW486475B (en) | 1996-12-26 | 2002-05-11 | Ube Industries | Acid addition salt of optically active piperidine compound and process for preparing the same |
JP3107784B2 (ja) | 1996-12-26 | 2000-11-13 | 宇部興産株式会社 | 光学活性ピペリジン誘導体の酸付加塩及びその製法 |
US6252063B1 (en) | 1998-12-01 | 2001-06-26 | Merck & Co., Inc. | Crystalline salts of a carbapenem antibiotic |
TWI243162B (en) * | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
-
2003
- 2003-08-27 JP JP2004532725A patent/JP3746063B2/ja not_active Expired - Fee Related
- 2003-08-27 NZ NZ538956A patent/NZ538956A/en unknown
- 2003-08-27 UA UAA200502704A patent/UA78104C2/uk unknown
- 2003-08-27 ZA ZA200501418A patent/ZA200501418B/xx unknown
- 2003-08-27 PL PL03374664A patent/PL374664A1/xx not_active Application Discontinuation
- 2003-08-27 AU AU2003261748A patent/AU2003261748B2/en not_active Ceased
- 2003-08-27 EA EA200500420A patent/EA007613B1/ru not_active IP Right Cessation
- 2003-08-27 WO PCT/JP2003/010828 patent/WO2004020407A1/ja not_active Application Discontinuation
- 2003-08-27 EP EP03791325A patent/EP1535907A4/en not_active Withdrawn
- 2003-08-27 MX MXPA05002253A patent/MXPA05002253A/es active IP Right Grant
- 2003-08-27 CA CA002496623A patent/CA2496623C/en not_active Expired - Fee Related
- 2003-08-27 CN CNB038203367A patent/CN1310885C/zh not_active Expired - Fee Related
- 2003-08-27 BR BR0313831-3A patent/BR0313831A/pt not_active IP Right Cessation
- 2003-08-27 US US10/525,748 patent/US7304166B2/en not_active Expired - Fee Related
- 2003-08-27 KR KR1020057003211A patent/KR100582141B1/ko not_active IP Right Cessation
-
2005
- 2005-02-18 NO NO20050867A patent/NO20050867L/no not_active Application Discontinuation
- 2005-03-03 HR HR20050205A patent/HRP20050205A2/hr not_active Application Discontinuation
- 2005-03-28 EC EC2005005708A patent/ECSP055708A/es unknown
-
2006
- 2006-02-24 HK HK06102523A patent/HK1082497A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR100582141B1 (ko) | 2006-05-22 |
ECSP055708A (es) | 2005-08-11 |
CA2496623A1 (en) | 2004-03-11 |
PL374664A1 (en) | 2005-10-31 |
EP1535907A1 (en) | 2005-06-01 |
NO20050867L (no) | 2005-02-18 |
NZ538956A (en) | 2006-08-31 |
AU2003261748A1 (en) | 2004-03-19 |
UA78104C2 (en) | 2007-02-15 |
BR0313831A (pt) | 2005-07-05 |
WO2004020407A1 (ja) | 2004-03-11 |
JPWO2004020407A1 (ja) | 2005-12-15 |
KR20050059094A (ko) | 2005-06-17 |
MXPA05002253A (es) | 2005-06-08 |
EP1535907A4 (en) | 2006-11-29 |
CA2496623C (en) | 2008-02-12 |
CN1678575A (zh) | 2005-10-05 |
AU2003261748B2 (en) | 2006-11-23 |
CN1310885C (zh) | 2007-04-18 |
HK1082497A1 (en) | 2006-06-09 |
EA007613B1 (ru) | 2006-12-29 |
US20060106087A1 (en) | 2006-05-18 |
JP3746063B2 (ja) | 2006-02-15 |
HRP20050205A2 (en) | 2005-10-31 |
EA200500420A1 (ru) | 2005-08-25 |
US7304166B2 (en) | 2007-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200501418B (en) | Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives | |
AU2003227360A1 (en) | Novel amide derivatives or salts thereof | |
AP1850A (en) | Spiroindolineplperidine derivatives | |
EG24050A (en) | Heterocylocarboxamide derivatives | |
AU2003255492A1 (en) | Heterocyclic derivatives | |
HK1077068A1 (en) | Azolidinone-vinyl fused-benzene derivatives | |
IL166121A0 (en) | Indole-3-sulphur derivatives | |
EP1522540A4 (en) | AZAARENE DERIVATIVES | |
PL376475A1 (en) | N-substituted-2-oxodihydropyridine derivatives | |
GB0315870D0 (en) | Heterocyclic derivatives | |
AU2003302238A8 (en) | 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors | |
IL166426A0 (en) | N-biarylmethyl aminocycloalkanecarboxamide derivatives | |
HK1073102A1 (en) | Sulphonic acid salts of mandelic acid derivatives | |
AU2003268687A1 (en) | Novel salt of 2-acylaminothiazole derivative | |
AU2003222659A8 (en) | 23-o-substituted 5-o-mycaminosyltylonide derivatives | |
AU2003229459A1 (en) | Methods of using thiazolidinedithione derivatives | |
EP1531854A4 (en) | O-DERIVATED NOCATHIACIN DERIVATIVES | |
GB0213488D0 (en) | 2-Naphthamide derivatives | |
AU2003232362A8 (en) | 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors | |
AU2003243397A8 (en) | Homo-camptothecin derivatives | |
GB0220962D0 (en) | Heterocyclic derivatives | |
HUP0203929D0 (en) | New use of substituted alkyl-piridazinone derivatives | |
GB0311957D0 (en) | Heterocyclic derivatives | |
AU2003274043A1 (en) | Novel use of dioxocin-5-on derivatives | |
GB0209993D0 (en) | Heterocyclic derivatives |